Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Accumulated Expenses (2022 - 2024)

Adial Pharmaceuticals' Accumulated Expenses history spans 3 years, with the latest figure at $413557.0 for Q3 2024.

  • For Q3 2024, Accumulated Expenses rose 1278.52% year-over-year to $413557.0; the TTM value through Sep 2024 reached $413557.0, up 1278.52%, while the annual FY2023 figure was $421365.0, 56.26% down from the prior year.
  • Accumulated Expenses for Q3 2024 was $413557.0 at Adial Pharmaceuticals, up from $335156.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.7 million in Q1 2022 and bottomed at $20000.0 in Q2 2023.
  • The 3-year median for Accumulated Expenses is $413557.0 (2024), against an average of $482680.3.
  • The largest annual shift saw Accumulated Expenses plummeted 97.05% in 2023 before it surged 1575.78% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $963327.0 in 2022, then crashed by 56.26% to $421365.0 in 2023, then decreased by 1.85% to $413557.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Accumulated Expenses are $413557.0 (Q3 2024), $335156.0 (Q2 2024), and $196118.0 (Q1 2024).